Neogenomics Inc (NASDAQ:NEO)

8.82
Delayed Data
As of Jul 06
 -0.43 / -4.65%
Today’s Change
6.85
Today|||52-Week Range
54.74
-74.15%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Medical/Nursing Services
MARKET CAP
$1.0B

Company Description

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Contact Information

NeoGenomics, Inc.
9490 NeoGenomics Way
Fort Myers Florida 33912
P:(239) 768-0600
Investor Relations:
123976806002726

Employees

Shareholders

Mutual fund holders57.01%
Other institutional32.87%
Individual stakeholders10.50%

Top Executives

Lynn A. TetraultChairman & Chief Executive Officer
Bill BonelloChief Financial Officer
Steven A. RossChief Information Officer & Vice President
David SholehvarPresident-Clinical Services
John MooneyChief Technology Officer